Emerging microbes & infections

mRNA vaccine targeting Zika and dengue viruses to prevent harmful immune reactions and protect in early animal tests

Updated

Abstract

The bispecific mRNA vaccine against Zika and dengue viruses achieved up to an 8-fold enhancement in neutralizing antibody titers compared to the standard vaccine.

  • The bispecific vaccine integrates separate modules designed to enhance both B-cell and T-cell responses.
  • The B-cell module combines Zika virus protein with a component that boosts antibody production.
  • The T-cell module includes shared parts of both viruses to stimulate immune responses without increasing the risk of antibody-dependent enhancement.
  • In tests with immunodeficient mice, the vaccine provided protection against both Zika and dengue virus infections.
  • The developed vaccine may offer a new approach for dealing with multiple viruses that can cause similar immune complications.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free